KEAP1 and neoplasm: In view of the fact that NRF2 upregulation is not associated with cancer initiation, but with tumour progression, it would be reasonable to suggest that the mutation in KRAS, or TP53, arises as an early event that precedes mutation in KEAP1, or mutation in NFE2L2, respectively.